JP2003528098A - 抗血栓症薬および抗凝血薬としてのｎ−（ヘテロ環式）ベンゼン−または−ピリジンスルホンアミド - Google Patents

抗血栓症薬および抗凝血薬としてのｎ−（ヘテロ環式）ベンゼン−または−ピリジンスルホンアミド

Info

Publication number
JP2003528098A
JP2003528098A JP2001568937A JP2001568937A JP2003528098A JP 2003528098 A JP2003528098 A JP 2003528098A JP 2001568937 A JP2001568937 A JP 2001568937A JP 2001568937 A JP2001568937 A JP 2001568937A JP 2003528098 A JP2003528098 A JP 2003528098A
Authority
JP
Japan
Prior art keywords
group
amino
carbonyl
sulfonyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2001568937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528098A5 (https=
Inventor
アルタンビュルジェ，ジャン−ミシェル
クレメ，ジェラール
ラサル，ジルベール
マトルギ，モスタファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2003528098A publication Critical patent/JP2003528098A/ja
Publication of JP2003528098A5 publication Critical patent/JP2003528098A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2001568937A 2000-03-23 2001-03-22 抗血栓症薬および抗凝血薬としてのｎ−（ヘテロ環式）ベンゼン−または−ピリジンスルホンアミド Ceased JP2003528098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/03724 2000-03-23
FR0003724A FR2806722B1 (fr) 2000-03-23 2000-03-23 Derives de n-(heterocyclylbutyl) benzene-ou pyridine sulfonamide, leur preparation et leur application en therapeutique
PCT/FR2001/000861 WO2001070736A1 (fr) 2000-03-23 2001-03-22 N-(heterocyclyl)benzene-ou pyridine sulfonamides comme agents antithrombotiques et anticoagulantes

Publications (2)

Publication Number Publication Date
JP2003528098A true JP2003528098A (ja) 2003-09-24
JP2003528098A5 JP2003528098A5 (https=) 2008-05-08

Family

ID=8848428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568937A Ceased JP2003528098A (ja) 2000-03-23 2001-03-22 抗血栓症薬および抗凝血薬としてのｎ−（ヘテロ環式）ベンゼン−または−ピリジンスルホンアミド

Country Status (34)

Country Link
US (1) US6680329B2 (https=)
EP (1) EP1268469B1 (https=)
JP (1) JP2003528098A (https=)
KR (1) KR100791693B1 (https=)
CN (1) CN1183128C (https=)
AR (1) AR029900A1 (https=)
AT (1) ATE269325T1 (https=)
AU (2) AU2001246617B2 (https=)
BG (1) BG65863B1 (https=)
BR (1) BR0109385A (https=)
CA (1) CA2401637C (https=)
DE (1) DE60103868T2 (https=)
DK (1) DK1268469T3 (https=)
EA (1) EA004986B1 (https=)
EE (1) EE05084B1 (https=)
ES (1) ES2222358T3 (https=)
FR (1) FR2806722B1 (https=)
HR (1) HRP20020762B1 (https=)
HU (1) HUP0300695A2 (https=)
IL (2) IL151619A0 (https=)
IS (1) IS2304B (https=)
ME (1) MEP17408A (https=)
MX (1) MXPA02009276A (https=)
NO (1) NO324835B1 (https=)
PL (1) PL204660B1 (https=)
PT (1) PT1268469E (https=)
RS (1) RS50370B (https=)
SI (1) SI1268469T1 (https=)
SK (1) SK286687B6 (https=)
TR (1) TR200402343T4 (https=)
TW (1) TWI290141B (https=)
UA (1) UA71667C2 (https=)
WO (1) WO2001070736A1 (https=)
ZA (1) ZA200206996B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102991A1 (ja) * 2004-04-19 2005-11-03 Daiso Co., Ltd. 非天然型アミノ酸の製造方法およびその中間体
US7750162B2 (en) 2004-04-19 2010-07-06 Daiso Co., Ltd. Process for preparation of nonnatural amino acid and intermediate thereof
JP2014527539A (ja) * 2011-08-29 2014-10-16 センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス） ウィッティヒ反応によるγ，δ−不飽和アミノ酸の汎用的な立体特異的合成

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1567497B1 (en) * 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
JP5492189B2 (ja) * 2008-04-09 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１０アンタゴニストである２−スルホニルアミノ−４−ヘテロアリールブチロアミド
US8859814B2 (en) * 2008-05-22 2014-10-14 Boehringer Ingelheim International Gmbh Alpha-substituted N-sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them
MX345259B (es) * 2010-01-28 2017-01-23 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasas similares a tripsina, y su preparación y uso.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208591A (ja) * 1994-11-25 1996-08-13 Synthelabo Sa ２−アミノベンゼンスルホン酸誘導体ならびに２−アミノベンゼンスルホニルクロリド誘導体とその製造法およびその合成中間体としての使用
JPH08239380A (ja) * 1994-12-23 1996-09-17 Synthelabo Sa １−オキソ−２−（フェニルスルホニルアミノ）ペンチルピペリジン誘導体、その製造及びその治療上の応用
WO1998022443A1 (fr) * 1996-11-22 1998-05-28 Synthelabo Derives de n-(imidazolylbutyle) benzenesulfonamide ayant une activite antithrombotique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756220B1 (fr) * 1996-11-27 1998-12-24 Lorraine Laminage Roue pour vehicule terrestre a moteur
FR2771094B1 (fr) * 1997-11-19 2000-02-04 Synthelabo Derives de piperidine-2-carboxylate, leur preparation et leur application en therapeutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208591A (ja) * 1994-11-25 1996-08-13 Synthelabo Sa ２−アミノベンゼンスルホン酸誘導体ならびに２−アミノベンゼンスルホニルクロリド誘導体とその製造法およびその合成中間体としての使用
JPH08239380A (ja) * 1994-12-23 1996-09-17 Synthelabo Sa １−オキソ−２−（フェニルスルホニルアミノ）ペンチルピペリジン誘導体、その製造及びその治療上の応用
WO1998022443A1 (fr) * 1996-11-22 1998-05-28 Synthelabo Derives de n-(imidazolylbutyle) benzenesulfonamide ayant une activite antithrombotique

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102991A1 (ja) * 2004-04-19 2005-11-03 Daiso Co., Ltd. 非天然型アミノ酸の製造方法およびその中間体
US7750162B2 (en) 2004-04-19 2010-07-06 Daiso Co., Ltd. Process for preparation of nonnatural amino acid and intermediate thereof
JP4752761B2 (ja) * 2004-04-19 2011-08-17 ダイソー株式会社 非天然型アミノ酸の製造方法およびその中間体
JP2014527539A (ja) * 2011-08-29 2014-10-16 センター ナショナル デ ラ リシェルシェ サイエンティフィック（シーエヌアールエス） ウィッティヒ反応によるγ，δ−不飽和アミノ酸の汎用的な立体特異的合成

Also Published As

Publication number Publication date
FR2806722B1 (fr) 2002-05-17
IS2304B (is) 2007-10-15
EA004986B1 (ru) 2004-10-28
PT1268469E (pt) 2004-10-29
HUP0300695A2 (hu) 2003-07-28
DE60103868D1 (de) 2004-07-22
DE60103868T2 (de) 2005-06-09
PL364988A1 (en) 2004-12-27
BG107130A (bg) 2003-06-30
CA2401637A1 (en) 2001-09-27
EE05084B1 (et) 2008-10-15
TWI290141B (en) 2007-11-21
KR20020081476A (ko) 2002-10-26
MXPA02009276A (es) 2003-05-23
SK13512002A3 (sk) 2003-03-04
SK286687B6 (sk) 2009-03-05
YU67002A (sh) 2005-07-19
UA71667C2 (uk) 2004-12-15
CA2401637C (en) 2009-11-10
DK1268469T3 (da) 2004-10-11
SI1268469T1 (en) 2004-10-31
EE200200540A (et) 2004-04-15
NO20024496L (no) 2002-11-22
IS6535A (is) 2002-08-30
NO20024496D0 (no) 2002-09-19
HK1051537A1 (en) 2003-08-08
BG65863B1 (bg) 2010-03-31
CN1183128C (zh) 2005-01-05
PL204660B1 (pl) 2010-01-29
AU4661701A (en) 2001-10-03
US6680329B2 (en) 2004-01-20
AU2001246617B2 (en) 2006-03-02
ATE269325T1 (de) 2004-07-15
HRP20020762B1 (en) 2005-02-28
HRP20020762A2 (en) 2003-12-31
NO324835B1 (no) 2007-12-17
KR100791693B1 (ko) 2008-01-03
ZA200206996B (en) 2003-09-01
IL151619A0 (en) 2003-04-10
AR029900A1 (es) 2003-07-23
IL151619A (en) 2009-05-04
ES2222358T3 (es) 2005-02-01
MEP17408A (en) 2010-06-10
BR0109385A (pt) 2003-06-03
US20030207920A1 (en) 2003-11-06
FR2806722A1 (fr) 2001-09-28
EA200200838A1 (ru) 2003-04-24
EP1268469B1 (fr) 2004-06-16
EP1268469A1 (fr) 2003-01-02
TR200402343T4 (tr) 2004-12-21
RS50370B (sr) 2009-11-10
WO2001070736A1 (fr) 2001-09-27
CN1426407A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
KR100199638B1 (ko) 비페닐 유도체
CN1803795B (zh) 用作抗变态反应药物的哌啶化合物
JP2002534503A (ja) アミド化合物
DE19753522A1 (de) Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2000053600A1 (en) Novel piperidine derivatives
CA2234967A1 (en) Fibrinogen receptor antagonists
CN101838271A (zh) 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物
JP2873025B2 (ja) １‐［モノ―もしくはビス（トリフルオロメチル）‐２‐ピリジニル］ピペラジンを含有する薬剤組成物
JP2002508780A (ja) 新規な化合物
KR100245955B1 (ko) 메타노안트라센화합물
AU2003269775B2 (en) Novel compounds
JP2001520628A (ja) 中枢神経系疾患の予防及び治療のための医薬組成物
TWI254706B (en) Cyclic amine compounds and pharmaceutical composition containing the same
JP2003528098A (ja) 抗血栓症薬および抗凝血薬としてのｎ−（ヘテロ環式）ベンゼン−または−ピリジンスルホンアミド
CN102884048B (zh) 用作hcn阻滞剂的氨基杂芳基衍生物
JPH06506956A (ja) ピリドンの新規な誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
JPWO1997000258A1 (ja) 三環性ベンゾアゼピン化合物
JPWO2003002535A1 (ja) 六員環式基を有する環状ジアミン化合物
JPH0543544A (ja) インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
HK40075584A (en) Kv3 enhancers for the treatment of cognitive disorders
HK1051537B (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
MXPA99007603A (en) Antitromboti agents
JPWO1999052894A1 (ja) 血小板凝集阻害作用を有する含窒素複素環化合物およびその医薬用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110803

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120117

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20120529